You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康希諾生物(06185.HK)宇學峰:吸入式新冠疫苗走在世界前列 目前內地已全面使用
阿思達克 11-07 11:50
康希諾生物(06185.HK)公司董事長兼首席執行官宇學峰以線上形式出席生物科技論壇時,糾正有關康希諾的吸入式新冠疫苗,是經口吸入,是吸到肺裡的一個疫苗,最近全國各地開始全面使用,目前這款疫苗走在世界前列,也是全球第一個經過吸入給藥的疫苗,海外回響也非常好,希望將來中國的創新發明走入全球。 他指,生物醫藥、生物經濟的發展面對的挑戰非常大,首先其專業性非常強,技術的好壞在經過驗證前是難以判斷,所以能否成功的不確定性也很難避免,正是生物醫藥本身面臨的挑戰,這是該行業特點而決定。若成功,帶來回報是巨大,不光是經濟,同時也是社會效應方面。例如疫苗,如果大家吸一口便能阻斷傳播,疫苗的所有費用,一天的GDP或就能補回來,這個投入帶來的回報是巨大。 他續指,其次生物醫藥不是獨立發展,實際是帶動行業相關的產業鏈發展,但目前整個產業鏈不完善;他表示,怎樣把產業鏈從原材料、設備、耗材諸如此類的東西能夠補齊,能夠形成一個很好的全球化環境,是生物醫藥產業面臨的挑戰,極大地影響整個生物經濟產業的發展。(ca/k) ~
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account